Navigation Links
New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs
Date:11/2/2010

SAN FRANCISCO, Nov. 2, 2010 /PRNewswire/ -- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

"Scientific innovation has brought measurable rewards such as reduced development times, higher success rates for cancer drugs, and increased investment and activity across the biopharmaceutical industry," said Lisa Natanson, senior analyst, Deloitte Recap LLC. "We see clear patterns of successful drug development from this study of a defined set of biotechnology companies that have produced innovative cancer drugs in the last decade."

By analyzing the drug development patterns of the Deloitte Recap BioPortfolio Index (RBI) companies, a select group of more than 150 biotechnology companies that have been tracked and benchmarked for more than a decade, Deloitte identified the following key findings:

  • FDA-approved oncology compounds all heavily utilized at least one (and some as many as four) special U.S. regulatory mechanisms, such as Fast Track designation, Orphan Drug status, or Accelerated Approval, to speed clinical development and reduce FDA transit times.
  • Orphan indications served as an initial market entry point to billion dollar markets followed by label expansion efforts to broaden the patient populations.
  • Innovative agents, such as those targeting receptor tyrosine kinases, achieved up to 31 percent approval success rates.

"Overall, the findings of this report demonstrate that the biotech industry is having a measurable impact on developing new therapies in the 'war on cancer,'" concluded Matthew Hudes, national managing principal of the biotechnology practice for Deloitte Co
'/>"/>

SOURCE Deloitte
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DUSA Pharmaceuticals Named to Deloittes 2010 Technology Fast 500 List of Fastest Growing Companies in North America
2. Virtual Radiologic Ranked 264th Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
3. China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program
4. Accuray Ranked Number 113 Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
5. Genoptix Ranked 41st Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
6. Deloitte Issue Brief: Mobile Personal Health Records May Offer Consumers Key to Technology-Enabled Self-Care
7. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
8. Time to Blow Up the Pharmaceutical Sales Model? New Deloitte Debate
9. Health Care Retail Clinics Continue Gradual Expansion Through 2012: Deloitte Center for Health Solutions Report
10. Deloitte Recap Launches New Solution for Clinical Development
11. Deloitte Report: Pharmaceutical Companies Patent Cliff Could Bolster Mergers and Acquisitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 ... kongestive Herzinsuffizienz (CHF) in seiner ersten klinischen ...   Die israelische Firma ... für Patienten mit kongestiver Herzinsuffizienz (CHF) entwickelt ... Finanzierungsvorhaben über 5 Mio. USD abgeschlossen hat. ...
(Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Uroplasty to Participate in the 27th Annual ROTH Conference 2Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... Sept. 7 Symmetry Medical Inc. (NYSE: ... the global orthopedic device industry and other medical markets, ... and Chief Financial Officer, is scheduled to present at ... at the Stifel Nicolaus 2010 Healthcare Conference in Boston, ...
... MORRISTOWN, N.J., Sept. 7 Watson Pharmaceuticals, Inc. (NYSE: ... Watson Laboratories, Inc., has received approval from the United ... New Drug Application (ANDA) for Zarah™ (drospirenone and ethinyl ... Bayer,s Yasmin ® . Watson has begun shipping the ...
Cached Medicine Technology:Symmetry Medical to Present at Two Upcoming Conferences 2Watson's Generic Yasmin® Receives FDA Approval 2
(Date:2/27/2015)... Cucamonga, CA (PRWEB) February 27, 2015 ... STEM”U”LATE Your Mind: Pi Day event on March 14, ... about RDI-Engineering’s services, demonstrations on how to use engineering ... The event will be hosted by Moreno Valley College’s ... STEM Student Success Center (SSC) in hopes to encourage ...
(Date:2/27/2015)... Is it reasonable – and appropriate – ... games, and possible to do so without causing impossible financial ... be at high risk for concern and could also need ... being addressed by two introductory bills, Int. 85 and ... month in New York City. More specifically, these bills ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Many ... for people’s health. Mercola.com has introduced organic cotton ... contain toxic flame retardant chemicals. Dr. Mercola’s Healthy ... design and better materials. Organic cotton is significantly ... Mercola’s organic bedding products are made by Naturepedic ...
(Date:2/27/2015)... to a Feb. 12, 2015 news release by Verastem, ... by killing cancer stem cells, has received orphan drug designation ... in the treatment of mesothelioma.* According to the release, orphan ... development of drugs for the treatment of rare diseases. ... Melinda Helbock, Founder of The Law Office of Melinda J. ...
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
Breaking Medicine News(10 mins):Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3Health News:Qualis Health Named Award Finalist for Care Transitions Work 2
... French scientists have made another breakthrough in the technology that ... researchers have successfully superposed light beams, which produces a state ... , Light beams that are simultaneously on and off ... faster than current computers based on bits, that are either ...
... Each condition encourages the other, study finds , , THURSDAY, Aug. ... of developing diabetes and so-called pre-diabetes rises steeply, a new ... up to four-and-a-half times more likely to develop diabetes compared ... likely to develop high blood sugar, according to the report ...
... better to female teachers, according to a new Canadian ... as readers when they worked with female research assistants ... study focused on 175 third- and fourth-grade boys who ... boys participated in a 10-week reading intervention to determine ...
... It helps people refrain from actions good and bad, experts ... ever been of "two minds" about doing something, a new ... the brain is responsible for initiating action, while a totally ... that action. , This newly identified region, involved in ...
... 2007,MSU engineering team designs innovative medical device,A Michigan State ... system that would allow people to be inexpensively screened ... Tongtong Li, assistant professor of electrical and computer engineering, ... Scheel, Thomas Casey and Kurtis Hessler teamed up with ...
... use of gastric bypass, banding, experts say , , WEDNESDAY, ... they,ve known for years, two major studies find that ... A U.S. study of almost 16,000 obese people found ... for gastric bypass. And a Swedish study of more ...
Cached Medicine News:Health News:Heart Attack Boosts Diabetes Risk 2Health News:Scientists Spot Brain's 'Free Will' Center 2Health News:Scientists Spot Brain's 'Free Will' Center 3Health News:MSU engineering team designs innovative medical device 2Health News:Weight-Loss Surgeries Extend Lives 2Health News:Weight-Loss Surgeries Extend Lives 3Health News:Weight-Loss Surgeries Extend Lives 4
... HearTwave II system is the ... T-Wave Alternans (MTWA) testing platform ... sudden cardiac death risk stratification. ... versatility as it can be ...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... Lenses are a family of single-use direct view ... a particular region of the retinal surface during ... than 1 gram and is formed and polished ... a human cornea. Lenses come in boxes of ...
... 30° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
Medicine Products: